Spoken Alpha
ANI PHARMACEUTICALS INC
ANI Pharmaceuticals develops, manufactures, and commercializes pharmaceutical products across three business segments: Rare Disease (including the retinal implants ILUVIEN and YUTIQ, and the ACTH therapy Cortrophin Gel), Brands (including products like Inderal and Vancocin), and Generics (a portfolio of over 120 generic drugs).
ANI PHARMACEUTICALS INC is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $1.61B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 5, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ANIP.
$ curl https://api.spokenalpha.com/v1/companies/ANIPFAQ
Spoken Alpha indexes ANIP's earnings call transcripts at https://spokenalpha.com/companies/ANIP. Each call links to attributed speakers and parsed analyst Q&A. ANI PHARMACEUTICALS INC's own investor relations page is at https://investor.anipharmaceuticals.com/.
ANI PHARMACEUTICALS INC (ANIP) held its most recent earnings call on 2026-05-08, covering fiscal Q1 2026.
ANI PHARMACEUTICALS INC (ANIP) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-05 | — | $1.77 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-06 | $1.82 | $1.67 | +9.0% | $266.0M | — | — | EODHD |
| Q1 FY2026 | 2026-05-07 | $1.68 | $0.96 | +75.0% | $237.5M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $2.33 | $2.04 | +14.2% | $247.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-06 | $2.04 | $1.77 | +15.3% | $227.8M | — | — | EODHD |
| Q2 FY2025 | 2025-08-07 | $1.80 | $1.42 | +26.8% | $211.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-08 | $1.70 | $1.38 | +23.2% | $197.1M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.55 | $0.29 | -100.0% | $190.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-07 | $1.34 | $1.09 | +22.9% | $148.3M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $1.02 | $0.95 | +7.4% | $138.0M | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $1.21 | $1.00 | +21.0% | $137.4M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $1.00 | $0.86 | +16.3% | $131.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $1.27 | $0.84 | +51.2% | $131.8M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $1.28 | $0.67 | +91.0% | $116.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $1.17 | $0.35 | +100.0% | $106.8M | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $0.76 | $0.67 | +13.4% | $94.2M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $0.64 | $0.55 | +16.4% | $83.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $0.13 | $0.22 | -40.9% | $73.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.12 | $0.09 | -100.0% | $64.5M | — | — | EODHD |
| Q4 FY2021 | 2022-03-14 | $0.54 | $0.74 | -27.0% | $60.9M | — | — | EODHD |
Source: EODHD. ANIP reported actuals as published; sparse fields render as —.